Navigation Links
InspireMD Reports Results for Period Ended Dec. 31, 2012
Date:2/4/2013

e $500,000 in revenue recorded in the quarter ended Sept. 30, 2012. As previously noted, the prior quarter was negatively affected by stocking and selling disruptions caused by a realignment of the Company's distributors in advance of the presentation of the MASTER trial at the TCT.

- Gross profit for the Dec. 31, 2012 period was $803,000, compared to $621,000 for the Dec. 31, 2011 period, up nearly 30% owing to higher revenue and lower production costs.

- Total operating expenses for the Dec. 31, 2012 period were $5.2 million, compared to $8.9 million in the Dec. 31, 2011 period, a decrease of $3.7 million. The decrease was attributable to a $5.6 million decrease in G&A expenses (mainly due to timing of the recording of share-based compensation related to board members) in the Dec. 31, 2012 period. This decrease was offset by a $0.9 million one-time royalties buyout expense, an increase in sales and marketing activities of $0.6 million (primarily related to the TCT meeting and subsequent launch of MGuard EPS), and an increase of $0.4 million in R&D expenses (mainly to support clinical trials).

- The loss from operations for the Dec. 31, 2012 period was ($4.4 million), compared to ($8.2 million) for the Dec. 31, 2011 period.

- Net income of $3.6 million related to the revaluation of contingently redeemable warrants, less financial and tax expenses of $1.1 million, brought final net income for the Dec. 31, 2012 period to ($1.9 million), or ($0.11) per basic and diluted share, compared to a final net income of ($8.2 million), or ($0.49) per basic and diluted share for the Dec. 31, 2011 period. The weighted average number of shares of common stock used in computing net loss per share (basic and diluted) was 17.7 million for the quarter just ended, and 16.7 million for the prior year's quarter.

- At Dec. 31, 2012, cash and cash equivalents stood at approximately $5.4 million, compared to $10.3 million at June 30, 2012.

K
'/>"/>

SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
2. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
3. InspireMD Reports Results For Period Ending Sept. 30, 2012
4. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
5. InspireMD to Present at Harvard Investors Group on June 27 in New York
6. InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York
7. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
8. InspireMD Announces First Quarter 2012 Financial Results
9. BRICS NPWT Market and Pressure Relief Devices Industry Analysis in New Research Reports at ReportsnReports.com
10. Trimedyne Reports Financial Results For The Quarter And Fiscal Year Ended September 30, 2012
11. Perrigo Reports Record Second Quarter Revenue, Adjusted Earnings and Operating Cash Flow
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Fla. , Aug. 3, 2015  Charleston ... initiation of its second clinical development program with ... candidate, CL-H1T.  CL-H1T contains fast-dissolving ... being developed as a treatment for migraine headache ... "Many patients with migraine headaches also ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
(Date:8/3/2015)... Israel , August 3, 2015 ... it received the statistical analysis of results from a study ... the BVX-005 phase II trial which took place in 2012, ... not exist at the time of the study- in particular ... the epidemic in the United States ...
Breaking Medicine Technology:Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3
... SCOTTSDALE, Ariz. and WASHINGTON, June 15, 2011 The ... and CAQH CORE ® (Committee on Operating Rules ... collaborate on activities related to harmonizing electronic data interchange ... NCPDP and CAQH CORE began exploring the ...
... Endologix, Inc. (Nasdaq: ELGX ), developer and ... today that it has received U.S. Food and Drug ... AFX™ Endovascular AAA System, for the treatment of abdominal ... Annual Meeting of the Society for Vascular Surgery (SVS), ...
Cached Medicine Technology:NCPDP and CAQH CORE Partner on Harmonizing Operating Rules and Standards Across Healthcare 2NCPDP and CAQH CORE Partner on Harmonizing Operating Rules and Standards Across Healthcare 3Endologix Announces FDA Approval of AFX™ Endovascular AAA System 2Endologix Announces FDA Approval of AFX™ Endovascular AAA System 3
(Date:8/3/2015)... ... August 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a ... to present at the Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am ... subsequent archived replay of the Company’s presentation may be accessed via the investor relations ...
(Date:8/3/2015)... ... August 03, 2015 , ... It’s 25 ... Lava Springs, California’s northernmost and among its least visited State Parks. The volcanic ... whose main outflow is at Ahjumawi Lava Springs, part of the Fall River ...
(Date:8/3/2015)... ... August 03, 2015 , ... A July 9 article from ... rooms in recent years, according to the American Dental Association. According to a study ... visits went from 1.1 million in a single year to 2.2 million a year. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... decline by 39 percent, according to market research compiled for the National Association ... the U.S. Department of Labor, Bureau of Labor Statistics. As the number of ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dignity Health named Dr. Norris A. Baldwin, ... Room – Gilbert, opening in August. The new facility is licensed under ... Valley. , “Dr. Baldwin is an excellent leader and will ensure our new ...
Breaking Medicine News(10 mins):Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3
... DEXTER, Mich., Oct. 16 ReCellular, Inc., ... used wireless phones and,accessories, today announced it ... Cellular ( http://www.consumercellular.com ), one of,the nation,s ... to,collect wireless handsets for recycling from their ...
... 16 HLTH Corporation,(Nasdaq: HLTH ) today announced ... ended September 30, 2007 at approximately 4:00 pm (ET) ... announced, HLTH Corporation,s 84% owned,subsidiary, WebMD Health Corp. (Nasdaq: ... financial results for the three months ended September 30,2007 ...
... Pharmaceuticals,Corporation (NASDAQ: ASPV ; TSX: ASV) today ... $62 million for the third,quarter of 2007 compared ... quarter,of 2006. As previously announced, Aspreva will ... 2007. The Company will hold a conference,call and ...
... from yogurt(TM) in an easy-to-swallow caplet., VANCOUVER, ... launch of AccuFlora Pro-Biotic Acidophilus, a combination of,five ... and,supports a healthy immune system with the good ... to MayoClinic.com, there is growing public and scientific,interest ...
... of G&D, Dr. Michael Cleary (Stanford University School of ... critical player in the establishment of leukemia stem cells, ... leukemia (MLL) is a distinctive type of leukemia ... by the presence of a break and rearrangement of ...
... CHICAGO, Oct. 16 The Cambridge Group, a ... Carrie Shea,principals of the firm. Mr. Miller ... and,industry experience to The Cambridge Group. In his ... improvements in senior,executive and consulting positions. In his ...
Cached Medicine News:Health News:ReCellular Named Exclusive Cell Phone Recycling Partner for Consumer Cellular 2Health News:ReCellular Named Exclusive Cell Phone Recycling Partner for Consumer Cellular 3Health News:HLTH Corporation Announces Third Quarter Earnings Release Date and Conference Call 2Health News:Aspreva Announces Preliminary Revenues for Third Quarter 2007 2Health News:Aspreva Announces Preliminary Revenues for Third Quarter 2007 3Health News:Aspreva Announces Preliminary Revenues for Third Quarter 2007 4Health News:Northwest Natural Products Introduces AccuFlora(R) 2Health News:The Cambridge Group Names Two New Principals 2
... Designed To Be Used With The Gills ... On The Cornea For Making Limbal Relaxing Incisions., ... The Gills Nomograms. 6mm & 8mm Chord Length ... Relaxing Incisions.5mm Inner Circle Assists In Sizing A ...
... This System Is Designed To Manually Dilate ... Efficacy. The Bimanual Technique Maximizes Safety By ... Parallel, Rather Than Perpendicular, To The Plane ... Risk Of Inadvertent Capsule Tears. Pupil Stretching ...
... To Rest Either Nasally Or Temporally ... Allowing Eyelids To Be Opened From ... Possible Aperture., ,Open And Close With ... To The Globe During Clear Corneal ...
... Unique Reversible Speculums Designed To Rest ... Flipping The Speculums Over, Allowing Eyelids ... Fissures To The Widest Possible Aperture.,Open ... Unobstructed Around-The-Clock Access To The Globe ...
Medicine Products: